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Summary Tumour localisation and tumour to normal tissue ratios of a chimeric anti-carcinoembryonic
antigen (CEA) monoclonal antibody (MAb), in intact form and as an F(ab')2 fragment labelled with 1251 and
131i, were compared in groups of nude mice bearing four different colon cancer xenografts, T380, Co 1l2 or
LoVo, of human origin, or a rat colon cancer transfected with human CEA cDNA, called '3G7'. For each
tumour, three to four mice per time point were analysed 6, 12, 24, 48 and 96 h after MAb injection. In the
different tumours, maximal localisation of intact MAb was obtained at 24 to 48 h, and of F(ab')2 fragment 12
to 24 h after injection. Among the different tumours, localisation was highest with colon cancer T380, with
64% of the injected dose per gram (% ID/g) for the intact MAb and 57% for its F(ab')2 fragment. while in the
three other tumours, maximal localisation ranged from 14 to 22% ID g-' for the intact MAb and was about
I1 % for the F(ab')2. Tumour to normal tissue ratios of intact MAb increased rapidly until 24 h after injection
and remained stable or showed only a minor increase thereafter. In contrast, for the F(ab')2 fragment, the
tumour to normal tissue ratios increased steadily up to 4 days after injection reaching markedly higher values
than those obtained with intact MAb. For the four different xenografts, tumour to blood ratios of F(ab')2
were about 2, 3 and 5 to 16 times higher than those of intact antibodies at 12, 24 and 96 h after injection,
respectively.
The concept of using monoclonal antibodies (MAbs) as car-
riers to deliver cytotoxic drugs, radioisotopes or toxins more
selectively into tumours continues to stimulate experimental
and clinical research. While radiolabelled antibodies by
themselves might become useful to eradicate solid tumours as
already shown in animal models (Cheung et al., 1986;
Buchegger et al., 1989, 1990; Senekowitsch et al., 1989), they
have the additional advantage in that they yield precise
biodistribution information concerning the selection of the
appropriate carrier for other forms of immunotherapy.
Clinically, in current phase I-II radioimmunotherapy trials
(Breitz et al., 1992; Press et al., 1989; Mach et al., 1991),
bone marrow toxicity is the major dose limiting side effect.
Therefore, it appears important to reduce the circulation time
and retention of radiolabelled antibodies in this organ for
radioimmunotherapy, as well as for two or three step
approaches using anti-tumour antibodies (avidin-biotin
antibodies, the antibody-enzyme-prodrug method or bi-
specific antibodies (Pervez et al., 1988; Bagshawe, 1990; Le
Doussal et al.,1990)).
The constant domains 2 and 3 of antibodies are responsi-
ble for both the long circulation times of intact immuno-
globulin G (IgG) and receptor mediated retention on white
blood cells and in the reticuloendothelial system, including
the bone marrow. It is therefore logical to use F(ab')2
fragments which will have a shorter circulation time and
cannot bind to cells through the Fc receptor.
Since the in vivo stability and tumour localisation capacity
of an antibody fragment may depend not only on its IgG
subclass but may also show individual variations for MAb
fragments within the same subclass, we used for the present
study a chimeric immunoglobulin F(ab')2 fragment for which
these parameters were known (Buchegger et al., 1992).
Chimeric MAbs as compared to mouse MAbs might have a
potential advantage in that they are less immunogenic in man
and can therefore be administered repeatedly for diagnostic
and therapeutic purposes. It has been shown that the F(ab')2
fragment of chimeric MAb CE25/B7 of the human IgG2
subclass gives a good antibody localisation with the T380
human colon tumour xenograft, and that it is much less
degraded than the F(ab')2 fragment from a chimeric anti-
CEA MAb of the same specificity but of the human IgG4
subclass.
The objectives of the present study were (A) to compare in
dual labelling experiments the in vivo tumour localisation
capacity of this selected F(ab')2 fragment with that of the
corresponding intact MAb, (B) to compare the tumour to
normal tissue ratios of the two antibody forms coinjected in
the same mice and (C) to compare these antibody forms in
different tumour xenografts that exhibit differential antibody
accessibility.
Materials and methods
Chimeric monoclonal antibody
The mouse-human chimeric monoclonal antibody used here
was derived from the murine anti-CEA MAb CE25/B7 (Buc-
hegger et al., 1992; Hardman et al., 1989) which is directed
against the epitope Gold 4 (Hammarstrom et al., 1989) of
carcinoembryonic antigen (CEA). The antibody has a high
specificity for CEA and does not crossreact with either NCA-
55 or NCA-95 (Buchegger et al., 1984) or other granulocyte
glycoproteins (Audette et al., 1987). It has been used in
patients for immunoscintigraphy or radioimmunotherapy
(Bischof-Delaloye et al., 1989; Mach et al., 1988). In the
present study, the chimeric MAb (human IgG2) derived from
CE25/B7 was selected because both this intact MAb and its
F(ab')2 fragment show high stability in vivo in nude mice.
The whole-body half-life of the intact chimeric IgG2 MAb
was 199 h as compared to 69 h for the chimeric IgG4 MAb.
The F(ab')2 fragment of human IgG2 subclass consistently
gave a higher tumour uptake and a longer circulating half-
life than F(ab')2 from IgG1 and IgG4 chimeric MAb (Bucheg-
ger et al., 1992).
Preparation ofintact MAb and its F(ab')2fragment
The intact chimeric anti-CEA MAb of the human IgG2
subclass was purified from ascites obtained in nude mice by
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ammonium sulfate precipitation (45% ammonium sulfate
saturation at 4°C) (Buchegger et al., 1992). The MAb was
redissolved and purified by DE52 cellulose (Whatman, Bals-
ton, UK) ion exchange chromatography using 0.02 M phos-
phate buffer pH 8. The corresponding F(ab')2 fragment was
obtained from purified intact MAb by pepsin digestion
(Lamoyi & Nisonoff, 1983), (Sigma, St. Louis, MO), 4%
(w/w) in acetate buffer pH 4 for 22 h at 37°C and size
chromatography on Sephadex G-150 (Pharmacia, Uppsala,
Sweden). Purified intact MAb gave a single homogeneous
band on SDS-polyacrylamide gel electrophoresis (PAGE,
polyacrylamide 7.5%) with an apparent MW of 150 kD,
containing more than 95% of the proteins. Purified F(ab')2
gave two close bands of about 105 and 110 kD on the same
SDS-PAGE with no detectable amounts of intact MAb (Buc-
hegger et al., 1992).
Labelling and characterisation ofintact MAb and ofthe
F(ab')2fragment
Batches of 50fig of intact MAb and 50 jig of its F(ab')2
fragment were labelled by the iodogen method using 100 ,uCi
(3.7 MBq) of '3'I or 100fCi of 1251. Intact MAb was labelled
three times with 1251 and once with "'1I, F(ab')2 three times
with '31I and once with 1251. Inversion of the isotopes for
injection into nude mice bearing Col12 xenografts showed
no significant differences of immunoreactivity or biodistribu-
tion in normal tissues. The paired labelling method allows
one to analyse biodistribution and tumour localisation of the
intact MAb and its F(ab')2 in the same animal, thus pro-
viding a comparison of results obtained in mice with identical
biological parameters.
The immunoreactivity of radiolabelled intact MAb and
F(ab')2 in vitro was determined in a binding assay on CEA
insolubilised on CNBr-Sepharose (Pharmacia). For both the
intact MAb and its F(ab')2 fragment, binding was between
90-96% for all preparations (mean binding ± standard
deviation was 94.1 + 1.6% for intact MAb and 93.0 ± 2.1%
for F(ab')2). Nonspecific binding to an irrelevant protein
(also coupled to CNBr-Sepharose) was always below 2%.
Analytical chromatography of the radiolabelled intact MAb
and its F(ab')2 on the same Sephadex G-200 column gave
two sharp peaks with no detectable amounts of aggregates.
Trichloroacetic acid precipitation gave more than 98% pro-
tein bound radioactivity for all preparations.
Nude mouse tumour model
Four CEA expressing colon carcinomas transplanted into
nude mice were used in these studies: the human colon
carcinomas T380 (Martin & Halpern, 1984), Col 12 (Mach et
al., 1974), and LoVo (Drewinko et al., 1976) and a rat colon
carcinoma transfected with human CEA cDNA, called 3G7
(Pelegrin et al., 1992). These tumours were serially trans-
planted subcutaneously into the right flank of 7-9-week-old
male 'Swiss' homozygous nu/nu mice, kept in aseptic condi-
tions. Twenty animals of an identical passage (selected out of
25 transplantations) were used for each experiment. The
heterotransplanted colon carcinoma T380 contains almost no
necrotic areas, is moderately differentiated, and contains
numerous pseudolumina that are rich in CEA (Martin &
Halpern, 1984). High amounts of CEA are also extractable
from the human colon carcinoma xenografts Co112 and
LoVo, but perfusion and vascular permeability are lower in
these tumours as compared to tumour T380 (Folli et al.,
1993). The human CEA transfected rat colon carcinoma 3G7
was shown to express I x 106 molecules of CEA per cell. This
CEA is anchored to the cell membrane by a glycophos-
pholipid moiety and is efficiently bound by different anti-
CEA MAbs (Pelegrin et al., 1992). More than 90% of the
transplants of each of the four tumour types entered into
exponential growth 1 to 2 weeks after subcutaneous injection
of 50 mm3 of minced tumour. The mice had their thyroid
blocked for uptake of free iodine by addition of Lugol iodine
(5%) solution into their drinking water (0.4 ml -1), from 3
days before the injection of radiolabelled antibodies up to the
end of the experiments. The experiments were performed in
accordance with the Swiss guidelines for experimental animal
studies.
Injection ofthe radiolabelled antibodies
About 2 weeks after tumour transplantations, 20 animals
grafted with different colon tumours, weighing between 0.1 g
and 0.8 g, were distributed into six groups of three or four
nude mice with similar mean tumour sizes. The intact MAb
and F(ab')2 fragment labelled with different iodine isotopes
were mixed in equal quantities (Pressman et al., 1957), and
300 1il of the mixture was injected intravenously into the tail
vein of the animals. The injected dose per mouse was: 1 jig of
intact MAb and 1 fig of its F(ab')2 fragment, each radiolabel-
led with 1.6 to 1.8 ,uCi of 1251I or '"II. As a control, one group
of three mice was injected with 1.5 mg of unlabelled parental
mouse anti-CEA MAb CE25/B7 (Hardman et al., 1989) 24 h
prior to injection of the radiolabelled antibodies. The excess
of unlabelled antibody saturates tumour CEA (CEA content
of tumours Co 12, LoVo and T380 has been shown to be 3
to 16 jig g-', (Folli et al., 1993)) and competes with the
radiolabelled intact MAb and fragment and thus allows one
to estimate the non-specific tumour localisation.
Dissection and analysis ofinjected animals
At different times post injection groups of three to four mice
were killed by CO2 inhalation, about 0.5 ml blood was taken
from the vena cava, the tumour, various organs and the
carcasses were dissected, weighed, and the radioactivity for
both iodine isotopes was measured in a dual channel gamma
scintillation counter. The data were corrected for the overlap
(14%) of '3'I gamma radiation into the 1251 channel and for
the physical half-life of both iodine isotopes. From the
differential radioactivity analysis, we could determine the
concentration of the intact MAb and the F(ab')2 fragment,
and this was expressed in terms of the percentage of the total
injected dose of radioactivity per gram of tissue (% ID g-1).
Whole-body (excluding tumour) half-lives were calculated for
both the intact MAb and the F(ab)'2. Tumour to normal
tissue ratios were calculated by dividing the radioactivity
concentration in the tumour by the corresponding radio-
activity concentration in the individual normal organs.
Statistical analysis
The paired labelling technique gave precise data on biodis-
tribution of the intact MAb as compared to the F(ab')2
fragment because the two antibody forms encounter identical
biological parameters in each animal. We have compared
statistically by the Student t-test the tumour-to-blood ratios
of intact MAb with those of the F(ab')2 for each group of
three to four animals dissected per time and per tumour.
Results
Biodistribution ofradiolabelled intact MAb and its F(ab')2
Biodistribution of the intact MAb and its F(ab')2 was
assessed by measuring radioactivity concentrations, expressed
as a percentage of the injected dose per gram tissue
(% ID g-1) in the tumour, blood and various organs at
different times after injection. Figure 1 and Tables I, II, and
III show the results of mean antibody concentrations, + 1
standard deviation, in the tumour and selected normal tissues
for mice bearing xenografts of tumour T380, Col12, LoVo
and 3G7. The results for normal organs and blood were
remarkably similar in the different experiments.
Among the different tumours, the highest antibody locali-
sation was obtained with tumour T380. The radiolabelled
intact MAb and its F(ab')2 fragment localised very rapidly in
this tumour transplant and both antibody forms reached686 C.-A. VOGEL et al.
about 48% ID g-' as early as 6 h after injection. Tumour
radioactivity progressively increased for intact MAb until
24 h after injection when it reached a mean maximum of
64% ID g-'. The F(ab')2 reached its maximal localisation at
12 h with 57% ID g-'. For both the intact MAb and its
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Figure 1 Biodistribution of 1251 labelled intact chimeric anti-
CEA MAb of the human IgG2 subclass, panel a, and of its I'll
labelled F(ab')2 fragment, panel b, injected simultaneously into
nude mice bearing xenografts of the human colon carcinoma
T380. The concentration of intact MAb a, and F(ab')2 fragment
b, per gram of tissue for tumour, liver, kidneys, lung, carcass and
blood is expressed as a percentage of the total injected radio-
activity after correction for the physical half-life of the isotopes.
A control group was pre-injected with an excess (1.5 mg) of
unlabelled anti-CEA MAb of identical specificity to saturate the
relevant tumour CEA epitope. 'Non-specific tumour localisation'
is shown at 24 h after injection for both the radiolabelled intact
MAb and the F(ab')2 fragment. Vertical lines represent stan-
dard deviation calculated from groups of three to four animals
per time point.
F(ab')2 fragment, the non-specific tumour localisation at 24 h
(determined in animals injected with 1.5 mg unlabelled anti-
CEA MAb) was relatively low, with mean values of 10.9 and
4.3% respectively, as compared to the specific tumour
localisations at the same time point, of about 64 and 41%,
respectively.
In the mice with the other colon cancer xenografts Co 112,
LoVo and 3G7, the localisation of the antibodies into the
tumour was lower for both the intact MAb and the F(ab')2.
As shown in Tables, I, II and III, maximal tumour uptake
for intact MAb was reached at 24 h for LoVo (14% ID g-')
and at 48 h for Coll2 and 3G7 (17 and 22% IDg-', respec-
tively). For the F(ab')2 fragment, the maximal tumour
localisation of about 11% IDg-' was observed at 12h for
LoVo and Co 12 and at 24h for the 3G7 tumour.
For all experiments, the decrease in radioactivity in the
normal organs was much slower for intact MAb as compared
to the F(ab')2. In blood for instance, the % IDg-' of the
intact MAb at 6h in the four experiments was 16 to 22%
(mean 20.5%) and at 96h it was 6 to 11% (mean 8.6%),
while for F(ab')2 the mean % ID g-' was 12.6% (range
9-14%) at 6 h and fell to very low values, 0.12% (range 0.11
to 0.15) at 96 h. The more rapid elimination of the F(ab')2 as
compared to intact MAb is further illustrated by the
measurement of their respective whole-body half-lives. For
intact MAb it was 169 ± 66 h while for the F(ab')2 fragment
it was almost 10 times lower, 17.2 + 0.8 h.
Tumour to normal tissue ratios
The ratios comparing the radioactivity concentrations in the
four different tumours with that of representative normal
organs, including liver, kidneys, lung and blood are shown in
Figures 2 to 5. The evolution of these ratios showed a
marked difference between the intact MAb and the F(ab')2
fragment. For the intact MAb, the mean tumour to blood
ratios in mice with tumours Col12, LoVo and 3G7 ranged
from 0.8 to 1.05 at 24h after injection. Surprisingly, these
ratios increased only slightly until 96 h after injection when
they were 1.0 for LoVo, 1.55 for Col12, and 2.1 for 3G7. In
mice with tumour T380, a high tumour to blood ratio of 5.4
was observed as early as 24 h after injection, but again this
ratio increased only slightly until 4 days after injection when
it reached 8.1. A very similar evolution of the tumour to
normal tissue ratios was observed concerning the com-
parisons with other organs.
In contrast, for the F(ab')2 fragment, tumour to normal
Table I Biodistribution of '3'I labelled intact MAb and its 125I labelled F(ab')2
Col 2 xenografts
fragment, obtained in mice bearing
Hours after injection
Non-specific
localisation
6 12 24 48 96 at 24ha
Intact MAb
Tumour 5.8 o.lb 11.6 3.2 12.5 2.4 17.3 1.8 12.8 ± 3.6 6.5 ± 0.7
Liver 6.4 1.3 4.3 0.4 3.7 0.4 3.3 0.2 2.0 ± 0.7 3.5 ± 0.3
Kidneys 5.7 ± 0.7 6.2 ± 0.8 5.0 ± 0.2 4.2 ± 0.3 2.7 ± 1.0 4.8 ± 0.2
Lung 7.4 0.6 8.6 0.7 8.0 1.0 6.9 0.8 4.1 ± 1.3 8.0 ± 0.8
Spleen 3.1±0.4 3.7±0.4 3.2±0.2 2.6±0.4 1.3±0.4 2.7±0.3
Muscle 0.6±0.1 0.9±0.1 1.3±0.3 1.1±0.1 1.1±0.3 1.1±0.0
Bone 1.8±0.4 1.9±0.3 1.8±0.3 1.8±0.4 2.0±0.4 1.7±0.1
Blood 16.3 ± 2.5 17.7 ± 0.9 15.2 + 0.7 12.3 + 0.8 8.3 ± 2.8 13.3 ± 0.5
F(ab')2 fragment
Tumour 6.4 ± 0.5 11.2 + 3.2 9.0 + 2.0 6.5 + 0.6 2.46 ± 0.41 3.3 ± 0.5
Liver 4.3±0.8 1.7±0.3 0.9±0.1 0.2±0.1 0.04±0.01 0.9±0.0
Kidneys 5.6 0.7 3.3 0.5 1.7 0.1 0.4 0.1 0.07 ± 0.03 1.8 ± 0.2
Lung 5.9±0.5 4.1±0.6 2.3±0.2 0.7±0.1 0.12±0.02 2.3 ±0.2
Spleen 2.6±0.2 1.6±0.3 0.9±0.1 0.2±0.1 0.05±0.02 0.8±0.1
Muscle 0.6 ± 0.1 0.6 ± 0.1 0.5 + 0.0 0.1 ± 0.0 0.05 ± 0.01 0.4 ± 0.0
Bone 1.4±0.3 1.0±0.1 0.6±0.1 0.3±0.0 0.08±0.01 0.6±0.0
Blood 9.4 1.4 5.8 0.6 2.9 0.2 0.7 0.1 0.11 ± 0.04 2.7 ± 0.1
aNon-specific tumour localisation at 24 h was obtained in mice after saturation of tumour CEA by pre-injection of the
animals with 1.5 mg unlabelled antibody of identical specificity. bMean percent injected dose per gram tissue ± 1
standard deviation (after correction for physical half-lives of the isotopes) was obtained from three to four mice analysed
at different times after injection.INTACT ANTI-CEA MAb vs F(ab')2 IN VIVO 687
Table II Biodistribution of 25I labelled intact MAb and its '3'I labelled F(ab')2 fragment, obtained in mice bearing
LoVo xenografts
Hours after injection
Non-specific
localisation
6 12 24 48 96 at 24ha
Intact MAb
Tumour 6.5 0.3b 11.7±2.1 14.2±2.4 12.5± 1.1 10.5±3.3 6.3±0.6
Liver 6.6 ± 2.2 4.6 ± 0.4 3.7 ± 0.3 3.0 ± 0.3 2.8 ± 0.6 3.3 ± 0.3
Kidneys 6.9 0.2 5.4 ± 0.6 5.1 ± 0.3 4.0 ± 0.5 3.3 ± 0.4 5.2 ± 0.6
Lung 11.2 2.7 9.2 ± 1.5 8.9 ± 1.3 7.2 ± 0.5 6.2 ± 1.0 7.6 ± 1.0
Spleen 4.2 0.3 4.3 ± 0.9 3.4 ± 0.2 2.4 ± 0.4 2.7 ± 0.7 2.8 ± 0.2
Muscle 0.7±0.2 1.0±0.1 1.4±0.2 1.3±0.2 1.2±0.3 1.2±0.2
Bone 2.7±0.0 2.1 ±0.3 2.4±0.1 2.0±0.1 1.7±0.2 2.2±0.3
Blood 22.6 1.3 19.0 ± 1.7 16.0 ± 1.4 13.2 ± 1.4 11.5 ± 3.7 15.4 ± 1.4
F(ab')2 fragment
Tumour 7.4 0.5 11.1 ± 2.3 9.0 ± 1.0 4.6 ± 0.5 1.34 ± 0.52 2.1 ± 0.3
Liver 4.6 1.3 2.1 ± 0.2 0.9 ± 0.1 0.3 ± 0.0 0.04 ± 0.01 0.8 ± 0.1
Kidneys 8.4±0.6 4.1 ±0.3 1.9±0.2 0.6±0.1 0.07±0.01 1.7±0.1
Lung 9.1 ± 1.8 5.4±0.8 2.7±0.5 0.8±0.0 0.15±0.01 2.3±0.2
Spleen 3.4±0.3 2.2±0.4 0.9±0.1 0.2±0.1 0.08±0.04 0.7±0.1
Muscle 0.8±0.2 0.8±0.1 0.5±0.0 0.2±0.0 0.03±0.01 0.4±0.0
Bone 2.5 0.1 1.4 0.2 0.9 ± 0.2 0.3 ± 0.0 0.06 ± 0.01 0.8 ± 0.1
Blood 14.1 ±0.9 7.6 0.7 3.1 ± 0.2 0.8 ± 0.1 0.11 ± 0.05 2.9 ± 0.2
abLegends as described in Table I.
Table III Biodistribution of 1251 labelled intact MAb and its 13'I labelled F(ab')2 fragment, obtained in mice bearing 3G7
xenografts
Hours after injection
Non-specific
localisation
6 12 24 48 96 at 24ha
Intact MAb
Tumour 7.3 0.7b 11.8 ± 2.8 17.9 ± 1.9 21.6 ± 2.9 17.7 ± 4.3 6.2 ± 1.7
Liver 7.4 1.4 4.1 ±0.7 5.0 0.4 2.8 0.3 2.2 0.2 4.4 0.4
Kidneys 6.8 ± 0.8 5.4 ± 0.8 4.9 ± 0.3 3.7 ± 0.1 2.6 ± 0.1 6.1 ± 2.3
Lung 7.5 0.5 8.5 1.0 9.1 0.2 6.2 0.3 4.7 0.2 7.2 2.3
Spleen 3.9±0.4 3.6±0.6 4.4 1.2 2.3±0.1 1.7±0.1 3.8 1.4
Muscle 0.7 0.1 1.0 0.1 1.2 0.2 1.2 0.0 1.1 0.2 1.4 0.2
Bone 2.1 ± 0.9 1.9 ± 0.1 1.8 ± 0.3 2.1 ± 0.3 1.5 ± 0.5 2.8 ± 1.7
Blood 22.0 1.5 18.7 2.1 16.9 1.6 11.9 0.7 8.3 1.6 15.0 2.4
F(ab')2 fragment
Tumour 7.2±0.8 8.9 1.8 11.4 1.1 8.8 1.0 3.70 1.31 2.6 1.2
Liver 5.6 0.9 1.8 0.2 1.3 0.1 0.3 0.1 0.04 0.01 1.4 0.5
Kidneys 8.4 0.8 3.7 0.4 2.3 0.2 0.7 0.1 0.12 0.03 2.4 0.5
Lung 8.3±0.8 4.5±0.3 3.3±0.2 1.1 0.1 0.22±0.02 2.5±0.6
Spleen 3.5±0.3 1.7±0.2 1.2±0.2 0.3±0.1 0.05±0.01 1.3±0.6
Muscle 0.7±0.1 0.6±0.0 0.5±0.1 0.2±0.0 0.04±0.01 0.5±0.1
Bone 1.6±0.9 1.1 0.0 0.7±0.1 0.3±0.0 0.04±0.01 0.9±0.3
Blood 14.4 1.1 6.8 0.6 3.6 0.4 0.9 0.1 0.12 0.05 3.3 0.6
abLegends as described in Table I.
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Figure 2 Tumour to normal tissue ratios obtained with '25I
labelled intact chimeric anti-CEA MAb (broken lines) and its '"'I
labelled F(ab')2 fragment (full lines), injected simultaneously into
nude mice bearing human colon carcinoma xenografts of T380.
The ratios shown are tumour to blood (0), tumour to liver (A),
tumour to kidneys (U) and tumour to lung (A) at different times
(6, 12, 24, 48, and 96 h) after injection. Vertical lines represent 1
standard deviation calculated from groups of three to four
animals.
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Figure 3 Tumour to normal tissue ratios obtained in nude mice
bearing human colon carcinoma xenografts of Co112. Legend is
as described in Figure 2, except that intact MAb was labelled
with 'l'I and F(ab')2 with 1251.
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Figure 4 Tumour to normal tissue ratios obtained in nude mice
bearing human colon carcinoma xenografts of LoVo. Legend is
as described in Figure 2.
tissue ratios increased steadily until 4 days after injection
(Figures 2 to 5). In mice bearing tumour T380 xenografts,
the tumour to blood ratio at 24 h was already 16.6 and
increased to 45 at 96 h after injection. This represents an
increase of tumour to blood ratios for F(ab')2 compared to
the values obtained with the intact MAb in the same animals
of 3.1-fold at 24 h and of 5.3-fold at 96 h (Table IV). The
tumour to blood ratios for the F(ab')2 fragment in the three
other groups of mice bearing tumours Col 12, LoVo and 3G7
were 3.1. 2.9 and 3.2 at 24 h, and 24.5, 14.5 and 34.9 at 96 h,
respectively. These results obtained with F(ab')2 represent an
advantage of tumour to blood ratios over the intact antibody
of 3- to 3.8-fold at 24 h and of 14.3- to 16.1-fold at 96 h after
injection (Table IV). Note the remarkably low variations oie
these results that are a consequence of the direct comparison
in each animal of intact MAb with the F(ab')2 fragment.
The tumour to blood ratios obtained with intact MAb
were compared statistically to those obtained with the
F(ab')2: for each group of three to four animals analysed at
the five different dissection times, and for all four tumours,
the differences for tumour to blood ratios between intact
MAb and F(ab')2 were statistically significant (Student t-test,
20 analysis). The statistical significance was low for five out
of 20 comparisons (2p<0.05), while for the 15 other com-
parisons the difference was highly significant (2p<0.01).
Discussion
The tumour uptake and biodistribution of F(ab')2 fragments
as compared to intact monoclonal antibodies has been the
subject of several studies, generally with the conclusion that
higher tumour to normal tissue ratios can be obtained with
this type of fragment (Buchegger et al., 1983; Wahl et al.,
1983; Colcher et al., 1983; Herlyn et al., 1983). Fragments of
smaller size, such as an Fab or even a single-chain Fv, have
been less frequently studied in animal models. While high
tumour to normal tissue ratios were obtained with such
fragments, the absolute amount localised in the tumour was
Figure 5 Tumour to normal tissue ratios obtained in nude mice
bearing rat colon carcinoma xenografts 3G7 transfected with
human CEA cDNA. Legend is as described in Figure 2.
generally very low (Buchegger et al., 1983; King et al., 1992;
Milenic et al., 1991).
Comparisons of intact MAbs with their fragments were
generally obtained using different groups of mice, bearing the
same, arbitrarily selected human tumour xenograft. In the
present study, we made this comparison using four different
colon tumour xenografts, taking advantage of the paired
labelling method and using kinetic analyses, to gain as much
information as possible. The results obtained with different
tumour xenografts, with a wide range of antibody uptakes
from relatively low to very high percentages of injected dose,
should be representative of what is observed with tumours in
patients. The kinetic evaluation of the tumour uptake and of
the tumour to normal tissue ratios at different times after
injection allows one to draw some useful conclusions con-
cerning the F(ab')2 fragment as compared to intact antibody,
for both clinical immunoscintigraphy and radioimmuno-
therapy.
In addition, this direct comparison of intact MAb and
F(ab')2 in the same mice with the same tumour by the paired
labelling method (Pressman et al., 1957) gives more reliable
results since all biological properties of the tumour (and of
the mice), such as blood flow, vascular permeability and
vascular volume are the same for the intact MAb and for the
F(ab')2 fragment.
Recently, we have shown that F(ab')2 fragments from
chimeric human-mouse MAbs of different subclasses give
different tumour uptakes and different circulating half-lives in
nude mice (bearing human colon carcinoma xenografts of
T380). We found that the F(ab')2 from the human IgG2
subclass gave the highest tumour uptake and the longest
half-life in blood as compared to F(ab')2 fragments from
other chimeric antibody subclasses.
In the present study, we used this selected F(ab')2 and
compared it with the intact chimeric anti-CEA MAb of
human IgG2 subclass from which it was derived. In three out
of four tumours, T380, LoVo and Col12, maximal localisa-
tion of the F(ab')2 occurred at 12 h post injection and was
only slightly lower than the maximal localisation obtained
Table IV Increase of tumour to blood ratios obtained with F(ab')2 as compared
to those obtained with intact MAb, at different times after injection (mean
increase ± 1 SD)
Hours after Number of
injection mice T380 Co112 LoVo 3G7
6 3 1.7 0.2a 1.9 0.1 1.8 0.2 1.5 0.1
12 3-4 2.2 0.1 2.9±0.2 2.4±0.1 2.1 0.0
24 4 3.1 0.2 3.8±0.2 3.3±0.3 3.0±0.1
48 3-4 5.0±0.5 6.3 0.6 6.2±0.5 5.5±0.9
96 3 5.3 1.7 15.5±2.7 14.3± 1.7 16.1 8.0
'Increase of tumour to blood ratios was obtained by dividing the tumour to
blood ratio for F(ab')2 fragment by the respective ratio observed for intact MAb.
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with the intact MAb at 24 or 48 h. In the tumour 3G7,
maximal localisation with the F(ab')2 fragment occurred
relatively late (24 h) and reached only half of the maximal
localisation obtained with the intact MAb, that was
measured at a late time after injection (48 h). Thus, it
appears that in tumours with rapid uptake of both antibody
forms such as T380, the fragment can reach maximal tumour
localisations similar to those of the intact MAb. In contrast,
in a tumour with very slow antibody uptake such as 3G7, the
maximal localisation of the fragment remains below that of
the intact MAb, probably because during the slow process of
tumour localisation, a large part of the F(ab')2 is ex-
creted.
Concerning tumour to normal tissue ratios, for the three
tumours with low antibody uptake (Co 12, LoVo, and 3G7),
the blood radioactivity concentration of intact antibodies
remained similar to that of the tumours, even at later times
after injection, while for F(ab')2 the blood radioactivity con-
centration was already 3-fold lower than in the tumour at
24 h and 6- to 10-fold lower at 48 h after injection. The
blood radioactivity concentration is of major concern during
radioimmunotherapy (Buchegger et al., 1991; Siegel et al.,
1990) since bone marrow irradiation, which is the limiting
factor of this therapy, is due in great part to circulating
radiolabelled antibodies (Press et al., 1989). It is not possible
to directly measure bone marrow irradiation in mice, but we
have recently shown by precise measurements in a rat model
that mean bone marrow radioactivity is about 29 to 40% of
that in the blood after injection of '311-labelled intact
antibodies or F(ab')2 fragments (Buchegger et al., 1991). In
the present study, the observation time for intact antibody
was too short to calculate precise integral irradiation doses,
but the marked difference in the evolution of tumour to
blood ratios confirms and extends earlier observations
obtained at selected time points (Buchegger et al., 1983; Wahl
et al., 1983; Colcher et al., 1983; Herlyn et al., 1983).
Tumour to blood ratios with the F(ab')2 fragment were
significantly increased as compared to intact MAb, even at 6
to 24 h after injection, and continued to rise, reaching values
14 to 16 times higher than those obtained with intact MAb at
96 h for the three tumours with low antibody uptake.
In order to obtain similar tumour radiation doses, higher
amounts of radiolabelled F(ab')2 than of intact antibodies
would have to be injected into mice. Nevertheless, the
marked differences in tumour to normal tissue ratios
obtained here indicate that in radioimmunotherapy, mice
treated with F(ab')2 fragments would be exposed to less
whole-body and bone marrow radiation than mice treated
with intact antibodies while delivering the same dose to the
tumour. These results are in agreement with those observed
in a comparative radioimmunotherapy performed in T380
tumour bearing nude mice where for the same tumour dose,
50% more blood radiation dose was calculated for intact
antibodies as compared to F(ab')2 (Buchegger et al.,
1990).
Elevated tumour to normal tissue ratios obtained with
F(ab')2 fragments are equally important for immunoscinti-
graphy since they allow a better interpretation of tumour
images in patients (Bischof-Delaloye et al., 1989). Addition-
ally, the advantages of fragments might also be important for
immunoscintigraphy or radioimmunotherapy approaches that
use two or three step tumour localisation techniques, such as
avidin-biotin-antibody (Pervez et al., 1988) or bispecific
antibody-radiohapten (Le Doussal et al., 1989, 1990; Good-
win et al., 1988) or antibody-enzyme-prodrug (Bagshawe,
1990), which all strongly depend on a high tumour to normal
tissue ratio of antibody at the time of the second or third
injection.
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